<scp>MRD</scp> Assessment in Patients With Acute Myeloid Leukemia Aged ≥ 60 Years Treated With a 10‐Day Decitabine Schedule Versus Intensive Chemotherapy in the <scp>AML21</scp> Study
Adriano Venditti(University of Rome Tor Vergata), Francesco Buccisano(University of Rome Tor Vergata), Maria Ilaria Del Principe(University of Rome Tor Vergata), Michael Lübbert(University of Freiburg), Annalisa Imovilli(Azienda Sanitaria Unità Locale di Reggio Emilia), Monia Lunghi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paola Fazi(Fondazione Gimema Onlus), Marco Vignetti(Fondazione Gimema Onlus), Stefan Suciu(St James's University Hospital), Huls Gerwin(University Medical Center Groningen), Carella Am(Casa Sollievo della Sofferenza), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Lanza Francesco(Azienda Unità Sanitaria Locale Della Romagna), Pierre W. Wijermans(Radboud University Nijmegen), Giraut Anne(European Organisation for Research and Treatment of Cancer), Agostino Tafuri(Azienda Ospedaliera Sant'Andrea), Olivieri Attilio(Ospedali Riuniti di Ancona), Anna Candoni(University of Udine)
Cited by 1
Related Papers
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k